SCLX icon

Scilex Holding

16.31 USD
+1.72
11.79%
At close Updated Oct 24, 4:00 PM EDT
Pre-market
After hours
16.79
+0.48
2.94%
1 day
11.79%
5 days
28.43%
1 month
-42.95%
3 months
52.15%
6 months
268.17%
Year to date
6.81%
1 year
-47.81%
5 years
-95.27%
10 years
-95.27%
 

About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Employees: 31

0
Funds holding %
of 7,500 funds
Analysts bullish %
0
Positive news %
Price charts implemented using Lightweight Charts™